Insulinoma medical therapy: Difference between revisions
No edit summary |
|||
| Line 25: | Line 25: | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Disease]] | |||
[[Category:Endocrinology]] | |||
[[Category:Mature chapter]] | |||
{{WikiDoc Help Menu}} | |||
{{WikiDoc Sources}} | |||
Revision as of 23:12, 7 October 2015
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [3]Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [4]
|
Insulinoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Insulinoma medical therapy On the Web |
|
American Roentgen Ray Society Images of Insulinoma medical therapy |
|
Risk calculators and risk factors for Insulinoma medical therapy |
Overview
The predominant therapy for insulinoma is surgical resection. Supportive therapy for insulinoma includes octerotide, endoscopic ultrasound guided alcohol ablation, radiofrequency ablation, embolization, diazoxide and chemotherapy.
Medical Therapy
- Endoscopic ultrasound guided alcohol ablation[1]
Medications such as diazoxide and somatostatin can be used to block the release of insulin for patients who are not surgical candidates or who otherwise have inoperable tumours.
Streptozotocin is used in islet cell carcinomas which produce excessive insulin. Combination chemotherapy is used: either doxorubicin + streptozotocin, or fluorouracil + streptotozocin in patients where doxorubicin is contraindicated.[2]
In metastasizing tumours with intrahepatic growth, hepatic arterial occlusion or embolization can be used. [3]
References